Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Phase 1/2
39
about 11 years
1–40
4 sites in FL, MD, NY
What this study is about
This trial is testing if an investigational drug, Nivolumab, can be safely administered after a half-matched bone marrow transplant and if the drug will help prevent or delay relapse of sarcomas. Investigators are also trying to learn more about how the drug changes blood and/or tumors in participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Nivolumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
infusion
Primary: Adverse events attributed to Nivolumab for patients enrolled in this study
Secondary: Overall survival
Oncology